NeuroOne Q2 Loss Widens to $11.2M While Cash Fuels Mid-2026 Pilot Study
NeuroOne posted a fiscal Q2 net loss of $11.2 million on revenue of $0.4 million, compared with a $7.1 million loss and $0.3 million in the year-ago period. Cash and equivalents totaled $23.5 million as of March 31, funding ongoing R&D and preparations for a mid-2026 pilot study of its neurovascular access device.
1. Q2 Financial Results
NeuroOne reported fiscal Q2 revenue of $0.4 million, up from $0.3 million a year earlier, while net loss widened to $11.2 million from $7.1 million. The increase reflects elevated R&D investment into its neurovascular access technology and higher G&A costs to support corporate expansion.
2. Cash Position and Runway
Cash and cash equivalents stood at $23.5 million at March 31, providing funding for operations and R&D through mid-2027 under current burn rates. Management is evaluating potential financing or strategic partnerships to extend runway beyond the planned pilot study.
3. Corporate Business Update
Development of the flagship neurovascular access device is advancing with scaled manufacturing setups completed. A pilot clinical study is slated to begin in mid-2026, with regulatory submissions targeted upon initial feasibility results.